Blog Big Molecule Watch February 09, 2021

Celltrion begins Phase 3 trial of aflibercept biosimilar

Celltrion Inc. has begun a Phase 3 clinical trial of CT-P42, an aflibercept biosimilar referencing Regeneron’s Eylea.  The trial will enroll 300 patients with diabetic macular edema, and aims to compare CT-P42’s efficacy, safety, pharmacokinetics, and immunogenicity against Eylea.

Celltrion adds CT-P42 to its pipeline of other investigational biosimilars, including CT-P17 (referencing Humira), CT-P16 (referencing Avastin), CT-P39 (referencing Xolaire), CT-P41 (referencing Prolia), and CT-P43 (referencing Stelara).

The post Celltrion begins Phase 3 trial of aflibercept biosimilar appeared first on Big Molecule Watch.